Methylglyoxal (MGO) Lowering Cocktail to Reduce Appetite in Obese Individuals
Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Oct 15, 2021
Trial Information
Current as of August 19, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a special combination of ingredients, called the Methylglyoxal (MGO) Lowering Cocktail, which is designed to help reduce appetite in people who are obese. Researchers believe that certain compounds in our bodies, like methylglyoxal, may drive cravings for sugary foods, leading to overeating and weight gain. The goal of this study is to see if the MGO lowering cocktail, made up of several vitamins and compounds, can help adults with obesity (those with a body mass index or BMI over 27) eat less and potentially lose weight.
To be eligible for this trial, participants must be adults aged 18 and older who are classified as obese. However, individuals aged 50 and older are not eligible to participate. If you join the trial, you can expect to take the MGO lowering cocktail and be monitored for its effects on your appetite and weight. The study is currently not recruiting participants, but it aims to learn more about how this treatment could help address obesity and improve health.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Obese (BMI \>27) individuals
- Exclusion Criteria:
- • must be older than 50 years of age or older
About University Of California, San Francisco
The University of California, San Francisco (UCSF) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on translating scientific discoveries into effective therapies, UCSF collaborates with a diverse array of stakeholders, including healthcare professionals, industry partners, and patient communities. The university's research programs emphasize interdisciplinary approaches and leverage cutting-edge technology to address complex medical challenges. As a sponsor of clinical trials, UCSF is dedicated to maintaining the highest standards of ethical conduct and scientific rigor, ensuring the safety and well-being of participants while contributing to the broader medical knowledge base.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Francisco, California, United States
Patients applied
Trial Officials
Marshall Stoller, MD
Principal Investigator
University of California, San Francisco
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials